Aurobindo gets FDA nod for cephalexin capsules

Aurobindo Pharma Limited has announced that the US Food and Drug Administration (US FDA) has approved its cephalexin capsules 250 mg and 500 mg.

The product was being manufactured at its dedicated cephalosporin facility, unit VI, situated in Medak district, Andhra Pradesh.

The market opportunity for the cephalexin capsules is around $80 million.

Aurobindo has set up three multi-module formulation manufacturing facilities "� unit III, unit VI and unit XII. Earlier, products from unit III only contributed to the US sales.

With product approvals from the other two units, unit VI and unit XII, received in the last few days, the Hyderabad-based company will now be in a position to capitalise on the opportunity with immediate effect.